Profile data is unavailable for this security.
About the company
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
- Revenue in USD (TTM)4.12m
- Net income in USD-85.28m
- Incorporated2016
- Employees75.00
- LocationShattuck Labs Inc500 W. 5Th Street, Suite 100AUSTIN 78701United StatesUSA
- Phone+1 (512) 900-4690
- Websitehttps://www.shattucklabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anebulo Pharmaceuticals Inc | 0.00 | -8.20m | 49.67m | 2.00 | -- | 13.03 | -- | -- | -0.318 | -0.318 | 0.00 | 0.147 | 0.00 | -- | -- | 0.00 | -104.19 | -- | -113.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
Actinium Pharmaceuticals Inc | 81.00k | -42.62m | 51.72m | 49.00 | -- | 1.16 | -- | 638.47 | -1.52 | -1.52 | 0.0029 | 1.43 | 0.0009 | -- | -- | 1,653.06 | -45.12 | -46.98 | -50.13 | -52.71 | -- | -- | -52,620.99 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Syros Pharmaceuticals Inc | 4.15m | -131.56m | 52.01m | 68.00 | -- | -- | -- | 12.54 | -4.30 | -4.30 | 0.1222 | -0.2369 | 0.0288 | -- | -- | 61,000.00 | -91.46 | -54.44 | -112.06 | -64.32 | -- | -- | -3,171.70 | -772.82 | -- | -- | 1.18 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Intensity Therapeutics Inc | 0.00 | -15.08m | 52.21m | 5.00 | -- | 9.73 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
Shattuck Labs Inc | 4.12m | -85.28m | 53.93m | 75.00 | -- | 0.4876 | -- | 13.08 | -1.85 | -1.85 | 0.0883 | 2.32 | 0.029 | -- | -- | 54,986.67 | -60.08 | -29.14 | -66.66 | -32.42 | -- | -- | -2,067.99 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Gain Therapeutics Inc | 0.00 | -21.60m | 54.52m | 29.00 | -- | 4.56 | -- | -- | -1.33 | -1.33 | 0.00 | 0.4682 | 0.00 | -- | -- | 0.00 | -115.33 | -- | -170.44 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0396 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
Tevogen Bio Holdings Inc | 0.00 | 57.92m | 54.52m | 17.00 | 0.8501 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
Celularity Inc | 22.77m | -196.30m | 54.96m | 120.00 | -- | 1.18 | -- | 2.41 | -11.29 | -11.29 | 1.30 | 2.11 | 0.0836 | 2.90 | 2.39 | 189,758.30 | -72.04 | -19.19 | -94.47 | -20.99 | 29.66 | -- | -862.04 | -454.79 | 0.2086 | 1.37 | 0.4893 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
enVVeno Medical Corp | 0.00 | -20.60m | 56.12m | 31.00 | -- | 1.11 | -- | -- | -1.43 | -1.43 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -56.37 | -58.43 | -59.43 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Prenetics Global Ltd | 22.25m | -49.97m | 56.20m | 320.00 | -- | 0.2453 | -- | 2.53 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
Kezar Life Sciences Inc | 7.00m | -98.57m | 56.47m | 58.00 | -- | 0.3744 | -- | 8.07 | -1.35 | -1.35 | 0.0962 | 2.07 | 0.0316 | -- | -- | 120,689.70 | -44.47 | -32.54 | -47.84 | -34.09 | -- | -- | -1,408.11 | -4,308.11 | -- | -- | 0.0634 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 57.26m | 12.00 | -- | 5.63 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
Mural Oncology PLC | 0.00 | -173.30m | 58.10m | 117.00 | -- | 0.2822 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Enzo Biochem Inc | 33.34m | -17.55m | 58.15m | 179.00 | -- | 0.8386 | -- | 1.74 | -0.3516 | 0.9194 | 0.6633 | 1.35 | 0.4028 | 1.66 | 4.91 | 186,257.00 | -21.20 | -12.21 | -34.50 | -15.79 | 43.66 | 37.09 | -52.63 | -18.76 | 3.16 | -- | 0.053 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.12m | 14.97% |
Redmile Group LLCas of 21 Jun 2024 | 5.62m | 11.81% |
Prosight Management LPas of 31 Mar 2024 | 3.73m | 7.83% |
Adage Capital Management LPas of 31 Mar 2024 | 2.37m | 4.98% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.81m | 3.80% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 1.66m | 3.50% |
The Clark Estates, Inc.as of 30 Jun 2024 | 1.48m | 3.10% |
Geode Capital Management LLCas of 30 Jun 2024 | 904.07k | 1.90% |
Laurion Capital Management LPas of 31 Mar 2024 | 661.04k | 1.39% |
Millennium Management LLCas of 31 Mar 2024 | 612.38k | 1.29% |